| Quarterly Financials | Mar 2025 | Jun 2025 |
Revenue  | 165 | 119 |
| Expenses | 150 | 103 |
| EBITDA | 15 | 17 |
| Operating Profit % | 9 % | 14 % |
| Depreciation | 2 | 1 |
| Interest | 8 | 7 |
| Profit Before Tax | 7 | 9 |
| Tax | 1 | 2 |
| Net Profit | 6 | 7 |
| EPS in ₹ | 12.71 | 14.33 |
Fredun Pharmaceuticals
Fredun Pharmaceuticals
1,575.15
+75.00
(5.00%)
Key Fundamentals
Market Cap
708.30 Cr
EPS
44.83
PE Ratio
37.67
Dividend Yield
0.04 %
Industry
Healthcare 52 Week High
1,525.90
52 Week Low
635.00
PB Ratio
5.26
Debt to Equity
0.88
Sector
Pharmaceuticals Actual
Company News
View All News
Fredun Pharmaceuticals Launches India's First Pure Jain Dog Biscuit 'Snacky Jain'6 days ago
Fredun Pharmaceuticals has launched 'Snacky Jain', marketed as India's first pure Jain dog biscuit. The product is formulated without root vegetables or animal ingredients, adhering to Jain dietary principles. The company is initiating sales across six cities and has announced plans for expansion.
Fredun Pharmaceuticals has acquired Wagr.ai as part of its strategy to enter India's pet care sector. The acquisition aims to leverage advanced technology and expertise in pet nutrition to transform the market.
Fredun Pharmaceuticals Board Approves Preferential Issue of Equity Shares and Convertible Warrants at Rs 1,250 Per ShareSep 25, 2025
Fredun Pharmaceuticals Limited's Board of Directors approved the issuance of up to 652,360 equity shares and 573,600 convertible warrants through a preferential issue at Rs 1,250 per share. The equity shares have a face value of Rs 10 each with a securities premium of Rs 1,240. The convertible warrants can be converted into equity shares within 18 months from allotment date, with 25% consideration payable at application and balance at conversion. The issue targets both promoters and non-promoters across 65 proposed allottees, including promoters Fredun Nariman Medhora and Daulat Medhora, along with various investment funds and individual investors. The company scheduled an Extra-Ordinary General Meeting for October 22, 2025, to seek shareholder approval for the preferential issue. The issuance is subject to shareholder and regulatory approvals including BSE Limited.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,679.10 | #1 3,98,049.70 | 38.75 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 61.71 | |
6,621.50 | 1,75,222.50 | 76.19 | 9,712.00 | 18.67 | 2,191 | 26.74 | 72.60 | |
1,577.60 | 1,26,768.90 | 23.67 | 28,409.50 | 7.12 | 5,291 | 9.88 | 60.63 | |
3,584.30 | 1,19,599.80 | 60.49 | 11,539.40 | 6.99 | 1,911 | 19.91 | 53.74 | |
1,255.90 | 1,03,508.80 | #1 18.25 | 33,741.20 | 16.73 | 5,725 | 1.26 | 48.97 | |
2,476.60 | 1,01,344.60 | 53.48 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 47.04 | |
987.65 | 99,073.80 | 21.09 | 23,511.00 | 18.55 | 4,615 | 2.60 | 45.37 | |
1,940.00 | 89,121.90 | 23.79 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 46.82 | |
5,581.50 | 66,047.70 | 28.61 | 13,458.30 | 3.70 | 2,216 | 21.39 | 63.11 | |
1,101.00 | 64,254.10 | 19.04 | 32,345.60 | 9.43 | 3,484 | -10.24 | 50.87 |
Growth Rate
Revenue Growth
26.26 %
Net Income Growth
44.44 %
Cash Flow Change
96.95 %
ROE
14.72 %
ROCE
9.48 %
EBITDA Margin (Avg.)
4.01 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 23 | 43 | 56 | 79 | 105 | 141 | 162 | 187 | 257 | 308 | 487 |
| Fixed Assets | 8 | 15 | 16 | 16 | 31 | 31 | 30 | 32 | 39 | 47 | 53 |
| Current Assets | 13 | 28 | 35 | 52 | 73 | 109 | 130 | 153 | 216 | 257 | 428 |
| Capital Work in Progress | 1 | 0 | 4 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 240 |
| Other Assets | 14 | 29 | 36 | 52 | 74 | 110 | 131 | 155 | 218 | 260 | 0 |
| Total Liabilities | 23 | 43 | 56 | 79 | 105 | 141 | 162 | 187 | 257 | 308 | 487 |
| Current Liabilities | 16 | 32 | 41 | 43 | 53 | 86 | 87 | 74 | 140 | 167 | 327 |
| Non Current Liabilities | 4 | 7 | 8 | 14 | 13 | 14 | 32 | 45 | 21 | 19 | 18 |
| Total Equity | 3 | 4 | 7 | 22 | 39 | 41 | 43 | 68 | 96 | 122 | 141 |
| Reserve & Surplus | 1 | 1 | 2 | 19 | 35 | 37 | 39 | 63 | 84 | 115 | 137 |
| Share Capital | 3 | 3 | 5 | 3 | 4 | 4 | 4 | 4 | 5 | 5 | 5 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 0 | 1 | -1 | 1 | 0 | 2 | -2 | 1 | 1 | -2 |
| Investing Activities | -3 | -6 | -7 | -8 | -5 | -2 | -1 | -4 | -9 | -8 |
| Operating Activities | 2 | 3 | 4 | 17 | 1 | -11 | 0 | -2 | -14 | -0 |
| Financing Activities | 1 | 4 | 3 | -8 | 4 | 14 | -1 | 8 | 25 | 6 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Nov 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | May 2023 | Jun 2023 | Aug 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Apr 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 52.04 % | 52.04 % | 52.04 % | 51.27 % | 51.27 % | 51.27 % | 51.04 % | 51.04 % | 50.34 % | 50.15 % | 49.62 % | 49.62 % | 49.33 % | 49.31 % | 49.16 % | 49.17 % | 48.92 % | 49.17 % | 48.93 % | 48.93 % | 48.93 % | 48.93 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| DIIs | 1.88 % | 1.88 % | 1.88 % | 1.69 % | 1.69 % | 1.69 % | 1.68 % | 1.68 % | 1.66 % | 1.65 % | 1.64 % | 1.64 % | 1.61 % | 1.60 % | 1.60 % | 1.60 % | 1.59 % | 1.60 % | 1.59 % | 1.59 % | 1.59 % | 1.59 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 41.01 % | 40.99 % | 40.77 % | 41.56 % | 41.90 % | 41.81 % | 42.02 % | 42.08 % | 42.48 % | 43.07 % | 43.64 % | 43.60 % | 43.48 % | 43.49 % | 43.67 % | 44.02 % | 43.94 % | 43.89 % | 44.21 % | 44.55 % | 44.50 % | 44.52 % |
| Others | 5.07 % | 5.09 % | 5.32 % | 5.47 % | 5.13 % | 5.23 % | 5.25 % | 5.19 % | 5.52 % | 5.13 % | 5.10 % | 5.14 % | 5.58 % | 5.60 % | 5.58 % | 5.22 % | 5.55 % | 5.35 % | 5.27 % | 4.93 % | 4.98 % | 4.96 % |
| No of Share Holders | 0 | 1,993 | 2,301 | 3,681 | 3,674 | 3,573 | 3,620 | 3,678 | 3,901 | 4,521 | 4,609 | 4,625 | 4,627 | 4,635 | 6,315 | 7,507 | 6,840 | 7,511 | 8,018 | 8,121 | 7,976 | 7,906 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.6 | 1 | 0.65 | 0.66 | 0.7 | 0.7 | 0.7 | 0.7 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.42 | 0.24 | 0.56 | 0.14 | 0.08 | 0.09 | 0.1 | 0.1 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 22 Oct 2025 |  Extraordinary General Meeting | NA | 22 Oct 2025 | 1,306.50 | 1,575.15 |
| 18 Sept 2021 |  Dividend | ₹ 0.70 /share | 16 Sept 2021 | 415.70 | 454.45 |
| 22 Sept 2023 | Dividend | ₹ 0.70 /share | 22 Sept 2023 | 886.50 | 875.65 |
| 18 Jan 2024 | Extraordinary General Meeting | NA | 18 Jan 2024 | 872.05 | 837.70 |
| 23 Sept 2024 | Dividend | ₹ 0.70 /share | 23 Sept 2024 | 981.65 | 767.60 |
| 30 Sept 2024 |  Annual General Meeting | NA | 30 Sept 2024 | 788.20 | 755.65 |
| 26 Oct 2024 |  Quarterly Result Announcement | NA | 26 Oct 2024 | 774.70 | 726.85 |
| 04 Feb 2025 | Quarterly Result Announcement | NA | 04 Feb 2025 | 700.70 | 721.85 |
| 30 May 2025 | Quarterly Result Announcement | NA | 30 May 2025 | 724.55 | 771.00 |
| 30 Jul 2025 | Quarterly Result Announcement | NA | 30 Jul 2025 | 860.20 | 958.60 |
| 23 Sept 2025 | Dividend | ₹ 0.70 /share | 23 Sept 2025 | 771.65 | 1,216.75 |
| 30 Sept 2025 | Annual General Meeting | NA | 30 Sept 2025 | 1,211.90 | 1,309.50 |
Announcements
Corrigendum I To The Notice Of Extraordinary General Meeting.
1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release6 days ago
6 days agoCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 20188 days ago
8 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-CessationOct 06, 2025
Oct 06, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 01, 2025
Oct 01, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportOct 01, 2025
Oct 01, 2025Intimation Of Record Date For The Purpose Of EOGM Of The Company.Sep 30, 2025
Sep 30, 2025Notice Of Book Closure For The Purpose Of Extra Ordinary General Meeting To Be Held On 22Nd October 2025.Sep 30, 2025
Sep 30, 2025Notice Convening Extra-Ordinary General Meeting (EOGM) Of Fredun Pharmaceuticals LimitedSep 30, 2025
Sep 30, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateSep 30, 2025
Sep 30, 2025Announcement under Regulation 30 (LODR)-Change in ManagementSep 30, 2025
Sep 30, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMSep 30, 2025
Sep 30, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 27, 2025
Sep 27, 2025Closure of Trading WindowSep 26, 2025
Sep 26, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On 25Th September 2025 Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations)Sep 25, 2025
Sep 25, 2025Closure of Trading WindowSep 22, 2025
Sep 22, 2025Board Meeting Intimation for Prior Intimation Under Regulation 29 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended (The SEBI LODR
Regulations)Sep 22, 2025
Sep 22, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 09, 2025
Sep 09, 2025Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 ("SEBI Listing Regulations").Sep 08, 2025
Sep 08, 2025Intimation Of Record Date For The Purpose Of Final Dividend For The Financial Year 2024-25Sep 08, 2025
Sep 08, 2025Notice Of Book Closure For The Purpose Of 38Th Annual General Meeting (AGM)Sep 08, 2025
Sep 08, 2025Submission Of The 38Th Annual Report Of Fredun Pharmaceuticals Limited For The Financial Year 2024-25.Sep 08, 2025
Sep 08, 2025Reg. 34 (1) Annual Report.Sep 08, 2025
Sep 08, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 03, 2025
Sep 03, 2025Announcement under Regulation 30 (LODR)-Meeting UpdatesSep 02, 2025
Sep 02, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 23, 2025
Aug 23, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 06, 2025
Aug 06, 2025Audio Recording Of The Q1 FY26 Earnings Conference CallAug 01, 2025
Aug 01, 2025Audio Recording Of The Q1 FY25 Earnings Conference CallAug 01, 2025
Aug 01, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 31, 2025
Jul 31, 2025Appointment Of Non-Executive Independent Directors.Jul 30, 2025
Jul 30, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateJul 30, 2025
Jul 30, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 30, 2025
Jul 30, 2025Results For The Quarter Ended 30Th June 2025.Jul 30, 2025
Jul 30, 2025Board Meeting Outcome for Outcome Of Board MeetingJul 30, 2025
Jul 30, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 30, 2025
Jul 30, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 29, 2025
Jul 29, 2025Board Meeting Intimation for Prior Intimation For The Board Meeting Of The Company To Be Held On Wednesday 30 July 2025.Jul 14, 2025
Jul 14, 2025Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderJul 10, 2025
Jul 10, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 09, 2025
Jul 09, 2025Voluntary Disclosure - SEBI Adjudication Order Dated June 30 2025 (No Penalty Imposed)Jul 03, 2025
Jul 03, 2025Closure of Trading WindowJun 30, 2025
Jun 30, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 30, 2025
Jun 30, 2025Announcement under Regulation 30 (LODR)-DemiseJun 20, 2025
Jun 20, 2025Investors Presentation Issued By Fredun Pharmaceuticals Limited Stating Annual Review & Strategic Outlook For Growth In The Pharma IndustryJun 10, 2025
Jun 10, 2025Investor Presentation Of Fredun Pharmaceuticals LimitedJun 10, 2025
Jun 10, 2025Revised Outcome Of The Board Meeting Dated 30.05.2025May 31, 2025
May 31, 2025Standalone And Consolidated Audited Financial Results For The Quarter And Financial Year Ended March 31 2025 Along With Statement Of Assets And Liabilities And Cash Flow StatementMay 31, 2025
May 31, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 31, 2025
May 31, 2025Technical Indicators
RSI(14)
Neutral 78.74
ATR(14)
Volatile 65.34
STOCH(9,6)
Overbought 86.99
STOCH RSI(14)
Neutral 61.41
MACD(12,26)
Bullish 11.10
ADX(14)
Strong Trend 48.62
UO(9)
Bearish 61.81
ROC(12)
Uptrend And Accelerating 19.82
WillR(14)
Overbought 0.00
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
